NeuExcell Therapeutics, a leading biotechnology company focused on in vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gene therapy product NXL-004. This milestone represents significant progress...
Not all drug targets are created equal. For those that result in a tissue specific gain-of-function, the strategy can be not-so-straightforward. That’s exactly what’s going on in some forms of amyotrophic lateral sclerosis (ALS), such as those with a mutation in the...